Stay updated on Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the dosing regimen for patients with advanced Renal Cell Carcinoma, specifically in the administration of Nivolumab and Salvage Nivolumab + Ipilimumab as part of a Phase II clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:47.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a more detailed description, now titled 'Participation Criteria,' explaining that researchers look for people who fit specific eligibility criteria, such as general health condition or prior treatments. This change provides a clearer understanding of the criteria used to select participants for the study.
    Difference
    41%
    Check dated 2024-05-22T21:00:47.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:23:20.000Z thumbnail image

Stay in the know with updates to Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Frontline + Salvage Nivo + Ipi in Advanced RCC Clinical Trial page.